Differences in MPS I and MPS II disease manifestations
CS Hampe, BD Yund, PJ Orchard, TC Lund… - International journal of …, 2021 - mdpi.com
Mucopolysaccharidosis (MPS) type I and II are two closely related lysosomal storage
diseases associated with disrupted glycosaminoglycan catabolism. In MPS II, the first step of …
diseases associated with disrupted glycosaminoglycan catabolism. In MPS II, the first step of …
[HTML][HTML] Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome
A Arguello, R Meisner, ER Thomsen, HN Nguyen… - JCI insight, 2021 - ncbi.nlm.nih.gov
Abstract Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by
deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of …
deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of …
Characterization of motor function in mice developmentally exposed to ethanol using the Catwalk system: Comparison with the triple horizontal bar and rotarod tests
B Jacquez, H Choi, CW Bird, DN Linsenbardt… - Behavioural brain …, 2021 - Elsevier
Studies with human subjects indicate that ethanol exposure during fetal development
causes long-lasting alterations in motor coordination that are, in part, a consequence of …
causes long-lasting alterations in motor coordination that are, in part, a consequence of …
[PDF][PDF] Ex-vivo gene therapy treats bone complications of mucopolysaccharidosis type II mouse models through bone remodeling reactivation
和田美穂， ワダミホ - Molecular therapy. Methods & clinical development, 2021 - ir.jikei.ac.jp
Mucopolysaccharidosis type II is a disease caused by organ accumulation of
glycosaminoglycans due to iduronate 2-sulfatase deficiency. This study investigated the …
glycosaminoglycans due to iduronate 2-sulfatase deficiency. This study investigated the …